

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

June 17, 2025

To whom it may concern,

Company Name: DAICEL CORPORATION
Representative: Yasuhiro Sakaki, President and CEO
(Code: 4202, Prime Market of the Tokyo Stock Exchange)
Contact: Masahiko Hirokawa, Executive Officer, Deputy
General Manager, Corporate Support
Headquarters and General Manager, Investor
Relations & Corporate Communications
(Phone: +81-3-6711-8121)

(Corrections) Partial corrections to the Consolidated Financial Results for the Year Ended March 31, 2024(Under Japanese GAAP)

DAICEL CORPORATION hereby announces that there have been corrections made to the “Consolidated Financial Results for the Fiscal Year Ended March 31, 2024[Japanese GAAP]” released on May 9, 2024.

1. Reason for corrections

After the release of the “Consolidated Financial Results for the Year Ended March 31, 2024 [Japanese GAAP]”, we have found errors in the “Investment in equity method investees” under “6. Segment Information” and have corrected them.

2. Details of Corrections

The corrections are indicated with underlines.

6. Segment Information

(Before corrections)

Year ended Mar. 31, 2024

(Unit: Millions of Yen)

	Medical / Healthcare	Smart	Safety	Materials	Engineering Plastics	Others	Total	Corporate and eliminations	Consolidated
Net sales									
Outside customers	13,927	30,715	95,574	185,341	226,821	5,676	558,056	—	558,056
Intersegment sales	—	290	—	10,820	152	13,682	24,946	(24,946)	—
Total	13,927	31,005	95,574	196,161	226,974	19,359	583,003	(24,946)	558,056
Operating profit (loss)	791	(2,855)	2,991	42,741	18,301	422	62,393	—	62,393
Assets	15,866	45,990	120,871	237,644	312,250	6,621	739,244	99,924	839,169
Other									
Depreciation	989	2,681	6,906	11,741	8,132	549	31,001	1,969	32,970
Amortization of goodwill	59	—	—	—	—	—	59	—	59
Investment in equity method investees	—	—	—	10	3	—	14	—	14
Capital expenditure	1,892	2,482	9,333	16,896	45,696	402	76,703	754	77,458

- (Note) 1. The category of “Others” is a business segment not included in reportable segments and includes the membrane business and the transportation warehousing business.
2. The reconciliation of segment assets consists of elimination of intersegment receivables of ¥(1,653) million and unallocated corporate assets of ¥101,578 million. Corporate assets consist of surplus operating funds (cash and deposits), long-term investment funds (investment securities), properties held or used by the administration departments, basic research departments, etc. and others.
3. There is no difference between total operating profit (loss) and operating profit in the consolidated statements of income.

(After corrections)

Year ended Mar. 31, 2024

(Unit: Millions of Yen)

	Medical / Healthcare	Smart	Safety	Materials	Engineering Plastics	Others	Total	Corporate and eliminations	Consolidated
Net sales									
Outside customers	13,927	30,715	95,574	185,341	226,821	5,676	558,056	—	558,056
Intersegment sales	—	290	—	10,820	152	13,682	24,946	(24,946)	—
Total	13,927	31,005	95,574	196,161	226,974	19,359	583,003	(24,946)	558,056
Operating profit (loss)	791	(2,855)	2,991	42,741	18,301	422	62,393	—	62,393
Assets	15,866	45,990	120,871	237,644	312,250	6,621	739,244	99,924	839,169
Other									
Depreciation	989	2,681	6,906	11,741	8,132	549	31,001	1,969	32,970
Amortization of goodwill	59	—	—	—	—	—	59	—	59
Investment in equity method investees	—	—	—	10,485	3,658	—	14,143	—	14,143
Capital expenditure	1,892	2,482	9,333	16,896	45,696	402	76,703	754	77,458

- (Note) 1. The category of “Others” is a business segment not included in reportable segments and includes the membrane business and the transportation warehousing business.
2. The reconciliation of segment assets consists of elimination of intersegment receivables of ¥(1,653) million and unallocated corporate assets of ¥101,578 million. Corporate assets consist of surplus operating funds (cash and deposits), long-term investment funds (investment securities), properties held or used by the administration departments, basic research departments, etc. and others.
3. There is no difference between total operating profit (loss) and operating profit in the consolidated statements of income.